Explore Our Cancer Journals Collection
CANCER JOURNALS COLLECTION
The IOS Press Cancer Journals Collection features a portfolio of five international, rigorously peer-reviewed journals that promote translational medicine. They are dedicated to advancing research, identifying preventive methods, improving diagnosis and treatment, and working towards improving patient outcomes. The journals are committed to the highest ethical standards and best practices.
Journals are currently Gold Open Access or will transition as of January 2024.
We invite you to browse content and submit to IOS Press journals in cancer research and clinical oncology. Check the journal entries below to link to content, instructions for authors and manuscript submission guidelines.
CANCER JOURNALS COLLECTION
Bladder Cancer
bladdercancerjournal.com
iospress.com/bladder-cancer
Bladder Cancer is the official journal of the Bladder Cancer Advocacy Network and partners with Grand Rounds in Urology.
The only journal devoted exclusively to bladder cancer
The official journal of the Bladder Cancer Advocacy Network, Bladder Cancer is an international multidisciplinary journal that facilitates progress in understanding the epidemiology, etiology, molecular genetics, pathogenesis, pathobiology and pharmacology of tumors of the bladder and upper urinary tract with the objective of improving diagnosis, treatment and survivorship in patients. The journal is directed primarily at researchers and clinicians working on these areas, with some content aimed at patients/patient advocates with these conditions.
The Editors-in-Chief and Associate Editors are key opinion leaders who rigorously oversee many aspects of the article submission process including peer review and acceptance decisions in their respective areas of expertise.
Special Editorial Features
• Challenging Cases section with active community engagement on clinical approaches, managed by an Associate Editor
• Clinical Trials Corner
• Paper Alert section highlighting publications from numerous sources of interest to the bladder cancer community,
overseen by an Associate Editor
• Systematic Reviews curated by a team of Associate Editors
• Guest Blogs, welcoming submissions, subject to Editorial approval
Editors-in-Chief
Seth P. Lerner, MD, Baylor College of Medicine
Dan Theodorescu, MD, PhD, Cedars-Sinai Medical Center, Los Angeles
Seth P. Lerner, MD, received the 2023 American Urological Association’s Presidential Citation for dedication to clinical trials and studying the genetic foundations of bladder cancer and is the 2023 chair of the SWOG Cancer Research Network’s genitourinary research committee.
Indexing includes Web of Science, Scopus, PubMed Central, Directory of Open Access Journals (DOAJ)
Breast Disease
An International Journal
Now in its 43rd volume, a timely and important resource serving the information needs of scientists, clinicians, and policy makers
Breast Disease is an international peer-reviewed journal publishing papers on topics such as basic cellular and molecular biology, epidemiology, genetics, clinical research, imaging, and social and legal issues. The journal promotes cross-disciplinary scientific discovery and understanding the public implications of these advancements.
Editorial Features
• Ongoing publication in one continuous issue/volume per year
• Case Reports
• Research Advancements
• Systematic Reviews
Founding Editor
Edison T. Liu, MD, President and CEO of The Jackson Laboratory
CiteScore: 1.8**
Indexing includes Scopus, PubMed/MEDLINE, Chemical Abstracts
Cancer Biomarkers
iospress.com/cancer-biomarkers
Launched in 2005, among the most highly regarded journals concentrating on molecular biomarkers in cancer research
Cancer Biomarkers publishes content on the identification of markers associated with the prevention, detection, diagnosis, and treatment of cancer whether or not they are an integral part of the pathological lesion. The disease markers may include, but are not limited to, genomic, epigenomic, proteomic, cellular and morphologic, and genetic risk factors predisposing to the disease or indicating the occurrence of the disease. Data science, artificial intelligence, radiomics, and other molecular approaches, such as bulk and single cell genomic sequence analyses for biomarkers discovery, development, and validation in reference to cancer prevention and treatment, are accepted.
Special Editorial Features
• Important new findings focusing on molecular screening and early detection
• Introduction of innovative methodologies integrating new technologies such as AI
• Special Themed Issues including Applications of Artificial Intelligence in Biomarker Research
Editor-in-Chief
Sudhir Srivastava, PhD, MPH
Sudhir Srivastava, PhD, MPH, was awarded the 2022 Don Listwin Award for Outstanding Contribution to Cancer Early Detection.
Impact Factor: 2.2*
CiteScore: 5.2**
Indexing includes Web of Science, Scopus, PubMed/MEDLINE
Kidney Cancer
journalkidneycancer.com
iospress.com/kidney-cancer
Kidney Cancer partners with the Kidney Cancer Association and Grand Rounds in Urology
Since its launch in 2017, Kidney Cancer has been going from strength to strength
Kidney Cancer is an international multidisciplinary journal facilitating progress in understanding the epidemiology, etiology, genetics, molecular correlates, pathogenesis, pathobiology, and pharmacology of tumors of the kidney with the objective of improving diagnosis, treatment, and survivorship in patients. The journal is directed primarily at researchers and clinicians working on these areas, with some content aimed at patients/patient advocates with these conditions.
The Editors-in-Chief and Associate Editors are key opinion leaders who rigorously oversee many aspects of the article submission process including peer review and acceptance decisions in their respective areas of expertise.
Special Editorial Features
• Ongoing publication in one continuous issue/volume per year
• Clinical Trials Corner
• Special Themed Issues (forthcoming in 2024: Kidney Cancer Pathology)
• Systematic Reviews curated by a team of Associate Editors
Editors-in-Chief
Primo N. Lara, Jr., MD, University of California Davis
Peter Mulders, MD, PhD, Radboud UMC (Nijmegen)
Indexing includes Web of Science, Scopus, PubMed Central (selective coverage), Directory of Open Access Journals (DOAJ)
Tumor Biology
iospress.com/tumor-biology
The Official Journal of the International Society of Oncology and BioMarkers (ISOBM), published by IOS Press since 2021
Tumor Biology is a peer-reviewed, international journal providing an open access forum for experimental and clinical cancer research. It covers all aspects of tumor markers, molecular biomarkers, tumor targeting, and mechanisms of tumor development and progression. Studies in other areas of basic, clinical, and translational cancer research are also considered in order to promote connections and discoveries across different disciplines.
Special Editorial Features
• Conference Abstracts
• Important new findings for the scientific exploration and clinical implementation of new biomarkers
• Special Themed Issues including Lung Cancer Tumor Markers (forthcoming)
Editor-in-Chief
Magdalena Chechlinska, PhD, Dr Habil, Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw
CiteScore: 5.4**
Indexing includes Scopus, PubMed/MEDLINE, Directory of Open Access Journals (DOAJ)
*Journal Citation Reports (Source Clarivate, 2024)
**Scopus, 2024
Publish with Us
-
Peer Review
All our publications adhere to stringent peer review practices.
-
Ethics Policy
Read our general publication ethics guidelines before submission.
-
Open Access
Options are available to publish open access in all our journals.
-
Article Sharing Policy
Information about the sharing options for articles.
-
Institutional Deals
Check out the open access agreements per country.
-
Sustainable Development Goals
All 5 cancer journals support the United Nation’s SDG Publishers Compact.
